Abstract
Acute Kidney Injury (AKI) is a common syndrome in the clinic and has become a worldwide public health problem. Renal Ischemia-Reperfusion Injury (IRI) is the most common cause of AKI. So far, effective treatment is still lacking for renal IRI, resulting in a high mortality rate of AKI. Mesenchymal Stem Cells (MSCs), considered as a promising candidate for tissue repair and regenerative medicine have aroused an increasing concern in recent years for the capacity of self-renewal and multi-lineage differentiation. MSC-based therapy has drawn wide attention for its therapeutic potential in renal IRI. The administrated MSCs can alleviate the renal IRI and improve the renal function for its anti-inflammatory, immunomodulation properties. MSCs preferentially migrate into injured sites to play the role of tissue repair. Furthermore, MSCs can modify the microenvironment to promote the recovery of damaged renal tubular cells via paracrine factors. However, the poor kidney-directional homing and poor survival under ischemia environment have limited their beneficial effects. Genetic modification is an effective approach to increase the therapeutic action of MSCs. MSCs are modified with exogenous genes to enhance their innate properties. Here we review the current knowledge of gene-modified MSCs, their biological characteristics and applications in renal IRI.
Keywords: Mesenchymal stem cells, Genetic modification, Renal ischemia-reperfusion injury, Reactive oxygen species.
Current Gene Therapy
Title:Gene-modified Mesenchymal Stem Cell–based Therapy in Renal Ischemia- Reperfusion Injury
Volume: 17 Issue: 6
Author(s): Hongbo Xu, Cheng Chen, Linkun Hu*Jianquan Hou*
Affiliation:
- Department of Urology, The First Affiliated Hospital of Soochow University, 188 Shizi Rd, Suzhou 215006,China
- Department of Urology, The First Affiliated Hospital of Soochow University, 188 Shizi Rd, Suzhou 215006,China
Keywords: Mesenchymal stem cells, Genetic modification, Renal ischemia-reperfusion injury, Reactive oxygen species.
Abstract: Acute Kidney Injury (AKI) is a common syndrome in the clinic and has become a worldwide public health problem. Renal Ischemia-Reperfusion Injury (IRI) is the most common cause of AKI. So far, effective treatment is still lacking for renal IRI, resulting in a high mortality rate of AKI. Mesenchymal Stem Cells (MSCs), considered as a promising candidate for tissue repair and regenerative medicine have aroused an increasing concern in recent years for the capacity of self-renewal and multi-lineage differentiation. MSC-based therapy has drawn wide attention for its therapeutic potential in renal IRI. The administrated MSCs can alleviate the renal IRI and improve the renal function for its anti-inflammatory, immunomodulation properties. MSCs preferentially migrate into injured sites to play the role of tissue repair. Furthermore, MSCs can modify the microenvironment to promote the recovery of damaged renal tubular cells via paracrine factors. However, the poor kidney-directional homing and poor survival under ischemia environment have limited their beneficial effects. Genetic modification is an effective approach to increase the therapeutic action of MSCs. MSCs are modified with exogenous genes to enhance their innate properties. Here we review the current knowledge of gene-modified MSCs, their biological characteristics and applications in renal IRI.
Export Options
About this article
Cite this article as:
Xu Hongbo, Chen Cheng , Hu Linkun*, Hou Jianquan *, Gene-modified Mesenchymal Stem Cell–based Therapy in Renal Ischemia- Reperfusion Injury, Current Gene Therapy 2017; 17 (6) . https://dx.doi.org/10.2174/1566523218666180214094253
DOI https://dx.doi.org/10.2174/1566523218666180214094253 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeting Leukocytes in Immune Glomerular Diseases
Current Medicinal Chemistry Increased Severity of Acute Cerebral Ischemic Injury Correlates with Enhanced Stem Cell Induction as well as with Predictive Behavioral Profiling
Current Neurovascular Research Microvascular Function/Dysfunction Downstream a Coronary Stenosis
Current Pharmaceutical Design MicroRNAs as Potential Therapeutic Agents in the Treatment of Myocardial Infarction
Current Vascular Pharmacology Adverse Effects of Statins - Mechanisms and Consequences
Current Drug Safety Hydrogen Sulfide and Endothelial Dysfunction: Relationship with Nitric Oxide
Current Medicinal Chemistry Antioxidants in Treating Pathologies Involving Oxidative Damage: An Update on Medicinal Chemistry and Biological Activity of Stobadine and Related Pyridoindoles
Current Medicinal Chemistry Monoclonal Antibodies in Clinical Oncology
Anti-Cancer Agents in Medicinal Chemistry The Antioxidant Effects of Radix Astragali (Astragalus membranaceus and Related Species) in Protecting Tissues from Injury and Disease
Current Drug Targets Neurotrophic Factors in Combination: A Possible new Therapeutic Strategy to Influence Pathophysiology of Spinal Cord Injury and Repair Mechanisms
Current Pharmaceutical Design Anti-Diabetic Effects of Isolated Lipids from Natural Sources through Modulation of Angiogenesis
Current Molecular Pharmacology Histone Deacetylase Inhibitors Target Diabetes via Chromatin Remodeling or as Chemical Chaperones?
Current Diabetes Reviews Molecular, Cellular and Clinical Aspects of Intracerebral Hemorrhage: Are the Enemies Within?
Current Neuropharmacology Effect of Aging on Metabolic Pathways in Endothelial Progenitor Cells
Current Pharmaceutical Design SIRT1 as a Promising Novel Therapeutic Target for Myocardial Ischemia Reperfusion Injury and Cardiometabolic Disease
Current Drug Targets Diagnostic and Therapeutic Patents and Patent Applications on Biomarkers for Acute Kidney Injury
Recent Patents on Biomarkers The Mitochondrial Thioredoxin is Required for Liver Development in Zebrafish
Current Molecular Medicine Neuroprotection by Diazoxide in Animal Models for Cerebrovascular Disorders
Vascular Disease Prevention (Discontinued) Dopamine Administration in Very Low Birth Weight Preterm Infants:Emerging Issues on Endocrine Effects
Current Pediatric Reviews Drugs and Rhabdomyolysis: From Liver to Kidney
Current Vascular Pharmacology